Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With Relatlimab
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 18 Feb 2019 Planned End Date changed from 1 Oct 2022 to 1 Feb 2023.
- 18 Feb 2019 Planned primary completion date changed from 1 Oct 2022 to 1 Feb 2023.
- 03 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2018 to 1 Jan 2019.